SGNTUC-021 Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2 Breast Cancer Emergency Use

Investigator: Polly Niravath, MD

Study Coordinator: Pej Hemati

Status: Open Not Enrolling Number: NCT04220203

Phone: 713.441.3926

Protocol Number: PRO00024847


This is an expanded access, open-label, multicenter program of tucatinib in combination with capecitabine and trastuzumab in patients with previously treated unresectable locally advanced or metastatic HER2 breast cancer. The purpose of this program is to provide access to tucatinib in the United States before FDA approval.
More to Explore
Live Chat Available